Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
Global Alzheimers Therapeutics Market Report 2019 Companies included Merck, Pfizer, Novartis, Eisai, Actavis and Others
on March 21, 2019 at 7:47 am
#7th Edition Alzheimers Therapeutics market report recently has been published by market reports company. It features comprehensive market outlook based on historic data from 2013 to 2018 and ... […]
Neurological Biomarkers Market Foreseen to Grow Exponentially Over 2018-2025
on March 19, 2019 at 2:11 am
According to a new report published by Allied Market Research, titled, Customized Study on Neurological Biomarkers Market for Alzheimers and Parkinsons Disease: Global Opportunity Analysis and ... […]
Alzheimers' Answers, as the numbers affected grow
on March 18, 2019 at 7:07 pm
The numbers are already staggering: 5.8 million Americans are living with Alzheimer's Disease, 400-thousand of them in New York State alone. Predictions are that nearly 14 million will have the ... […]
Alzheimers and DNA shuffling
on March 15, 2019 at 6:01 pm
The National Institutes of Health estimates 5.5 million Americans suffer from Alzheimers disease. Theres no therapeutic way to slow or prevent the disease yet. $1M grant will fund broadband extension ... […]
Global Alzheimers Drug Market 2019 Industry Key Players, Share, Trend, Segmentation, Analysis & Forecast To 2024
on March 11, 2019 at 3:05 am
Alzheimers Drug market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. […]
‘I’ll develop Alzheimers in a decade, just like my father’ The heartbreaking news doctors have told young Norwich woman
on March 8, 2019 at 8:32 am
Laura Sides, 36, left her psychology degree course at Nottingham University in 2004 to care for her dad Dr Jeremy Sides, who died aged 60 in 2009 - the year after she lost her mum Sue suddenly to a ... […]
India- Alzheimers Drug Market 2019 Report By Application, By End-User ,Size, Share, Trend And Segment Forecasts To 2024
on March 6, 2019 at 9:45 pm
(MENAFN - GetNews) Market Analysis Research Report On 'Global Alzheimers Drug Market 2019 Industry Growth, Size, Trends, Share, Opportunities And Forecast To 2024 ' To Their Research Database. ... […]
Weekly Wellness: Advice for Alzheimers Caregivers
on February 11, 2019 at 11:05 am
If you have a loved one with Alzheimer’s (or dementia), you know how challenging it can be. The stress can be overwhelming for everyone involved. What we do know is that trying to keep our loved ones ... […]
Alzheimers Q & A: What services are provided at a behavioral health hospital for someone with Alzheimer's disease or dementia?
on January 27, 2019 at 3:05 pm
As baby boomers age, psychiatric hospitals will see more and more people with Alzheimer's and other forms of dementia. A behavioral health, or psychiatric hospital, can provide a wide range of care ... […]
via Bing News